MEM-ANT3310 is a next generation antibacterial combination that has been designed to make a significant impact on the growing problem of antimicrobial resistance in serious hospital infections.
MEM-ANT3310 combines the well-known carbapenem meropenem (MEM) with ANT3310, a breakthrough serine-beta-lactamase (SBL) inhibitor developed by Antabio. This combination has been designed to provide a unique coverage of priority Gram-negative pathogens including OXA-carbapenem resistant Acinetobacter baumannii (CRAB), KPC- and OXA- carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa (PA).
ANT3310 represents an important advance as its innovative structure completely inhibits the enzymes that confer resistance and as a result, restores MEM’s activity against these deadly pathogens.